The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

Table 1

Clinical characteristics of the patients included for the validation of the MDACC prognostic index.

	Patients (%)	Median (Q1, Q3)
Age (years)		67.4 (58.9–74.6)
<50	37 (7.7)
50–65	172 (35.6)
>65	274 (56.7)
Sex
Male	310 (64.2)
Female	173 (35.8)
Lymphocyte count (×10^9/L)		13.0 (8.6–22.6)
<20	346 (71.6)
20–50	93 (19.3)
>50	44 (9.1)
Hemoglobin (g/dL)		14.3 (13.1–15.3)
≤10	22 (4.6)
>10	461 (95.4)
Platelet count (×10^9/L)		185 (145–226)
≤100	27 (5.6)
>100	456 (94.4)
β2-microglobulin (mg/L)		2.15 (1.6–3.0)
Normal	239 (49.2)
1-2x ULN	184 (37.9)
>2x ULN	63 (12.9)
LDH (UI/L)		323 (271–393)
Enlarged node regions
≤2	395 (81.9)
>2	88 (18.2)
Splenomegaly
Yes	80 (16.6)
Not	403 (83.4)
Hepatomegaly
Yes	35 (7.2)
Not	448 (92.8)
Rai staging system
0-2	453 (93.8)
3-4	30 (6.2)
FISH
Del11q	34 (7.0)
Trisomy 12	57 (11.8)
Del13q	192 (39.8)
Del17p	21 (4.3)
Normal	179 (37.1)
ZAP70
Positive	29 (15.8)
Negative	154 (84.2)
CD38 )
Positive	79 (23.4)
Negative	259 (76.6)

Q1: quartile 1; Q3: quartile 3; ULN: upper limit normal; MDACC: MD Anderson Cancer Center.